Jaime Sheffler
Family · North Syracuse, NYNPI 1558849679
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.5% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $842 and has fallen 83.2% since, to $141 in 2025.
Across 87 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$369
- AstraZeneca$359
- OPKO Pharmaceuticals, LLC$162
- Amgen$134
- Vifor Pharma, Inc.$127
- Otsuka America Pharmaceutical, Inc.$80
- plus $661 from 20 others
What the payments were for
- Food & beverage$1,75192%
- Education$1428%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 15 | $369 |
| AstraZeneca(2 entities) | 17 | $359 |
| OPKO Pharmaceuticals, LLC | 7 | $162 |
| Amgen | 6 | $134 |
| Vifor Pharma, Inc. | 6 | $127 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| Ardelyx, Inc. | 3 | $67 |
| Aurinia Pharma U.S., Inc. | 3 | $63 |
| Boehringer Ingelheim | 2 | $54 |
| Calliditas Therapeutics US Inc. | 3 | $52 |
| Abbott | 2 | $49 |
| GSK | 2 | $36 |
| Merck | 2 | $35 |
| Fresenius USA Marketing, Inc. | 2 | $34 |
| Pfizer | 2 | $34 |
| Gilead | 1 | $30 |
| Seqirus USA Inc | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Cumberland Pharmaceuticals, Inc. | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Akebia Therapeutics Inc | 1 | $18 |
| Medtronic | 1 | $16 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$111
How this compares
$1,893 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 11 | $1,043 |
| Potassium Chloride | 13 | $736 |
| Torsemide | 16 | $540 |
| Furosemide | 34 | $307 |
| Amlodipine Besylate | 21 | $174 |
| Levothyroxine Sodium | 11 | $120 |
Paid to pharmacies, not to this prescriber.
Other family in North Syracuse
- Sheri HillNorth Syracuse$165K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.